"...announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent US10835501B2, which relates to pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis.
According to the CDC, approximately 28% of Americans over forty years of age are prescribed a statin for hyper
cholesterolemia. Current statin therapies are associated with adverse effects including myalgia. In US clinical practices, roughly 45% of patients discontinue statin use after 6 months use due to adverse effects..."